基于肌酐、胱抑素C或两者的GFR估算方程在常规医疗中的准确性
在瑞典斯德哥尔摩6174例转诊行单点血浆碘海醇清除率测量的成人中,评估基于肌酐、胱抑素C或两者的多种eGFR方程与实测GFR的准确性。结果显示,eGFRcr-cys方程偏倚小且P30接近90%,表现优于eGFRcr或eGFRcys方程;在eGFRcr方程中,CKD-EPI 2009和2021的偏倚较大且P30较低。
要点
- eGFRcr-cys方程表现最佳,P30接近90%,偏倚小。
- eGFRcr方程中CKD-EPI 2009和2021较EKFC 2021和RLM偏倚更大、P30更低。
- eGFRcr-cys方程在肝病、癌症和心力衰竭患者中表现良好。
核心结论
- eGFRcr-cys方程表现最佳,且在该瑞典队列中各方程间变异极小。
- CKD-EPI eGFRcr方程表现低于EKFC和RLM,可能反映人群特征和mGFR方法的差异。
研究设计与样本
- 横断面研究,纳入6174例转诊行单点血浆碘海醇清除率测量的成人,共9579次同时测量的肌酐和胱抑素C。
主要发现
- 平均年龄56岁,中位mGFR为62 mL/min/1.73 m2,40%为女性。
- 合并症常见:心血管疾病30%、肝病28%、糖尿病26%、癌症26%。
- 所有eGFRcr-cys方程偏倚小且P30接近90%,表现优于eGFRcr或eGFRcys方程。
- eGFRcr方程中,CKD-EPI 2009和CKD-EPI 2021较EKFC 2021和RLM偏倚更大且P30更低。
- 各eGFRcys方程间表现无有意义差异。
临床怎么用
- 在常规医疗中,eGFRcr-cys方程可提供较小的偏倚和接近90%的P30。
- 实施eGFRcr方程需要在准确性和区域间统一性之间权衡。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New equations to estimate glomerular filtration rate based on creatinine (eGFRcr), cystatin C (eGFRcys) or both (eGFRcr-cys) have been developed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and the European Kidney Function Consortium (EKFC). There is a need to evaluate the performance of these equations in diverse European settings to inform implementation decisions, especially among people with key comorbid conditions. METHODS: We performed a cross-sectional study including 6174 adults referred for single-point plasma clearance of iohexol in Stockholm, Sweden, with 9579 concurrent measurements of creatinine and cystatin C. We assessed the performance of the CKD-EPI 2009/2012/2021, EKFC 2021/2023, revised Lund-Malmö (RLM) 2011 and Caucasian, Asian, Pediatric and Adult (CAPA) 2014 equations against measured GFR (mGFR). RESULTS: Mean age was 56 years, median mGFR was 62 mL/min/1.73 m2 and 40% were female. Comorbid conditions were common: cardiovascular disease (30%), liver disease (28%), diabetes (26%) and cancer (26%). All eGFRcr-cys equations had small bias and P30 (the percentage of estimated values within 30% of mGFR) close to 90%, and performed better than eGFRcr or eGFRcys equations. Among eGFRcr equations, CKD-EPI 2009 and CKD-EPI 2021 showed larger bias and lower P30 than EKFC 2021 and RLM. There were no meaningful differences in performance across eGFRcys equations. Findings were consistent across comorbid conditions, and eGFRcr-cys equations showed good performance in patients with liver disease, cancer and heart failure. CONCLUSIONS: In conclusion, eGFRcr-cys equations performed best, with minimal variation among equations in this Swedish cohort. The lower performance of CKD-EPI eGFRcr equations compared with EKFC and RLM may reflect differences in population characteristics and mGFR methods. Implementing eGFRcr equations will require a trade-off between accuracy and uniformity across regions.
引用
- Fu EL, Levey AS, Coresh J, et al. Accuracy of GFR estimating equations based on creatinine, cystatin C or both in routine care. Nephrol Dial Transplant. 2024. PMID: 37813817. doi:10.1093/ndt/gfad219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。